Role of mTOR inhibitor in the cellular and humoral immune response to a booster dose of SARS-CoV-2 mRNA-1273 vaccine in kidney transplant recipients

Simple item page
dc.contributor.authorPérez Flores, Isabel María
dc.contributor.authorJuárez Martín-Delgado, Ignacio
dc.contributor.authorAiffil Meneses, Arianne S.
dc.contributor.authorLópez Gómez, Ana
dc.contributor.authorCalvo Romero, Natividad
dc.contributor.authorRodríguez Cubillo, Beatriz
dc.contributor.authorMoreno de la Higuera, María Ángeles
dc.contributor.authorPeix Jiménez, Belén
dc.contributor.authorGonzález García, Raquel
dc.contributor.authorBaos Muñoz, Elvira
dc.contributor.authorArribi Vilela, Ana
dc.contributor.authorGómez Del Moral Martín-Consuegra, Manuel María
dc.contributor.authorMartínez Naves, Eduardo
dc.contributor.authorSánchez Fructuoso, Ana Isabel
dc.date.accessioned2024-01-10T12:16:40Z
dc.date.available2024-01-10T12:16:40Z
dc.date.issued2023-02-02
dc.description.abstractBackground: Immunocompromised patients have an increased risk of developing severe COVID disease, as well as a tendency to suboptimal responses to vaccines. The objective of this study was to evaluate the specific cellular and humoral adaptive immune responses of a cohort of kidney transplant recipients (KTR) after 3 doses of mRNA-1273 vaccine and to determinate the main factors involved. Methods: Prospective observational study in 221 KTR (149 non infected), 55 healthy volunteers (HV) and 23 dialysis patients (DP). We evaluated anti-spike (by quantitative chemiluminescence immunoassay) and anti-nucleocapsid IgG (ELISA), percentage of TCD4+ and TCD8+ lymphocytes producing IFNγ against S-protein by intracellular flow cytometry after Spike-specific 15-mer peptide stimulation and serum neutralizing activity (competitive ELISA) at baseline and after vaccination. Results: Among COVID-19 naïve KTR, 54.2% developed cellular and humoral response after the third dose (vs 100% in DP and 91.7% in HV), 18% only showed cell-mediated response, 22.2% exclusively antibody response and 5.6% none. A correlation of neutralizing activity with both the IgG titer (r=0.485, p<0.001) and the percentage of S-protein-specific IFNγ-producing CD8-T cells (r=0.198, p=0.049) was observed. Factors related to the humoral response in naïve KTR were: lymphocytes count pre-vaccination >1000/mm3 [4.68 (1.72-12.73, p=0.003], eGFR>30 mL/min [7.34(2.72-19.84), p<0.001], mTOR inhibitors [6.40 (1.37-29.86), p=0.018]. Infected KTR developed a stronger serologic response than naïve patients (96.8 vs 75.2%, p<0.001). Conclusions: KTR presented poor cellular and humoral immune responses following vaccination with mRNA-1273. The immunosuppression degree and kidney function of these patients play an important role, but the only modifiable factor with a high impact on humoral immunogenicity after a booster dose was an immunosuppressive therapy including a mTOR inhibitor. Clinical trials are required to confirm these results.
dc.description.departmentDepto. de Inmunología, Oftalmología y ORL
dc.description.facultyFac. de Medicina
dc.description.refereedTRUE
dc.description.statuspub
dc.identifier.citationPérez-Flores I, Juarez I, Aiffil Meneses AS, Lopez-Gomez A, Romero NC, Rodriguez-Cubillo B, Moreno de la Higuera MA, Peix-Jiménez B, Gonzalez-Garcia R, Baos-Muñoz E, Vilela AA, Gómez Del Moral M, Martínez-Naves E, Sanchez-Fructuoso AI. Role of mTOR inhibitor in the cellular and humoral immune response to a booster dose of SARS-CoV-2 mRNA-1273 vaccine in kidney transplant recipients. Front Immunol. 2023 Feb 2;14:1111569. doi: 10.3389/fimmu.2023.1111569
dc.identifier.doi10.3389/fimmu.2023.1111569
dc.identifier.issn1664-3224
dc.identifier.officialurlhttps://www.frontiersin.org/articles/10.3389/fimmu.2023.1111569/full
dc.identifier.relatedurlhttps://pubmed.ncbi.nlm.nih.gov/36817489/
dc.identifier.urihttps://hdl.handle.net/20.500.14352/92236
dc.journal.titleFrontiers in Immunology
dc.language.isoeng
dc.publisherFrontiers Media
dc.rightsAttribution 4.0 Internationalen
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subject.cdu612.017
dc.subject.keywordCOVID-19
dc.subject.keywordSARS-CoV-2 vaccine
dc.subject.keywordImmune response
dc.subject.keywordKidney transplantation
dc.subject.keywordmTOR
dc.subject.ucmCiencias Biomédicas
dc.subject.unesco2412 Inmunología
dc.titleRole of mTOR inhibitor in the cellular and humoral immune response to a booster dose of SARS-CoV-2 mRNA-1273 vaccine in kidney transplant recipients
dc.typejournal article
dc.type.hasVersionVoR
dc.volume.number14
dspace.entity.typePublication
relation.isAuthorOfPublication20948f45-92ce-4a9e-89b4-783c9696d0a1
relation.isAuthorOfPublication0894d58b-fe71-42aa-ad0a-19305823daa1
relation.isAuthorOfPublication3fcc2577-06c2-47f6-bf47-25a44263702b
relation.isAuthorOfPublication759562da-31b9-467b-82a2-f88052d2a9a2
relation.isAuthorOfPublicatione93526bf-b07c-4e2f-a128-2a86044d88e6
relation.isAuthorOfPublication520f2d09-78ca-4d34-b7bc-eb333044ae32
relation.isAuthorOfPublication52048564-29f6-4bd9-b131-6712b4fb871c
relation.isAuthorOfPublication.latestForDiscovery20948f45-92ce-4a9e-89b4-783c9696d0a1
Download
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
mRNA-1273 Tx H Clínico Frontier Immunol 2023.pdf
Size:
2.24 MB
Format:
Adobe Portable Document Format
downoload Download
Collections
Artículos